Introduction
Fibroid prevalence ranges from 20 to 50% in postmortem studies and 70% at hysterectomy for benign conditions [1] . Fibroids are present in >80% of African American women and >70% Caucasian women on ultrasound by age 50 [2] . Leiomyomas are thought to be present in 5-10% of infertile women [3] . Location, size, and distortion of the endometrial cavity are 3 factors that have been extensively reviewed with regard to fibroids and fertility. Intramural (IM) and submucosal (SM) fibroids impact fertility to varying degrees. SM fibroids correlate negatively with both spontaneous and assisted reproduc-tive technology (ART) pregnancy [4, 5] . Data are less conclusive on the effect of IM fibroids. While one study indicated a 47% decrease in the number of live births when IVF is conducted in the presence of IM fibroids [6] , another found no difference in IVF outcomes [7] . The wide variation in observed effect is likely attributable to heterogeneity in fibroid size, number, and proximity to the endometrium [4] .
Given that SM and selected IM fibroids diminish fertility, myomectomy prior to ART is commonplace. Hysteroscopic myomectomy has been associated with a 16% increase in fecundability and has been shown to be cost effective prior to ART [8, 9] . Pre-ART myomectomy may also have obstetric benefits [10] . However, evidence on the cost effectiveness of pre-IVF IM myomectomy is lacking. The purpose of this study was to determine when IM myomectomy prior to ART is cost effective.
Materials and Methods
We designed a decision tree mathematical model with sensitivity analysis utilizing published data as inputs for costs and probabilities. Since no patient data were used, institutional review board approval was not needed. A PubMed search was conducted on January 1, 2014 to determine ART ongoing pregnancy (OP) rate (OPR) in patients with IM fibroid(s) in situ vs. post-IM myomectomy. Only studies involving women undergoing IVF (with/without ICSI; hereafter referred to as 'ART') with autologous oocytes were selected. These studies revealed the presence of IM fibroids with/without myomectomy. To ensure quality, uniformity, and clinical applicability, we excluded studies involving only donor cycles and those having primary outcomes other than live birth, OP, or delivery. We also excluded one study for which all data were collected prior to January 1, 2000 and one study with extremely low/outlying OPRs among all groups (online suppl. fig. 1 ; for all online suppl. material, see www.karger.com/ doi/10.1159/000443391). This yielded 8 articles that were used to determine model inputs for ART outcome with IM myoma(s) in situ vs. post-myomectomy [6, [11] [12] [13] [14] [15] [16] [17] . Patients were mostly in their 30s. The sizes of IM fibroids considered varied. For most studies, fibroids did not distort the endometrial cavity (online suppl. . Two studies provided model inputs for OPR for ART following IM myomectomy. In the study by Bulletti et al. [11] , 2,004, patients decided whether to undergo myomectomy prior to initiation of ART. In contrast, all patients with fibroids abutting the endometrial cavity with <2 mm of intervening normal myometrium in the Surrey et al. [12] , 2005 analysis underwent myomectomy prior to ART. The group also noted that those with larger and more number of fibroids were more likely to undergo myomectomy by laparotomy.
Behera et al. [18] and Carls et al. [19] determined the perioperative costs of IM myomectomy, inclusive of procedural and inpatient costs of abdominal and laparoscopic myomectomy. Estimated costs were based on charges, and a macro-cost approach determined the market price. All costs were adjusted using the US Bureau of Labor Statistics inflation calculator to represent 2,014 dollars. Estimated ART/medication charges were obtained from geographically diverse US clinic websites/pharmacies and verified against those reported by 2 fertility finance organizations. Adjusted to 2,014 dollars, median ART charges (i.e. the average amount paid for one cycle of IVF or ICSI, including medications) were $15,701. Median myomectomy + ART charges were $25,439. These were used as surrogates for clinical costs (online suppl. table 3).
A decision tree compared cost per OP via ART in a theoretical patient with myoma(s) in situ vs. post myomectomy (online suppl. fig. 2 ). The probability of OP was then based on published data for each management strategy in the model. Our model considered a single cycle of ART.
Results
The average cost per OP in a patient with IM myoma(ta) in situ was calculated as cost per ART cycle ($15,701) divided by reported likelihood of OP per ART. The calculation was first performed using the median OPR reported in the literature (21.7%), yielding a cost per OP of $72,355.
This average cost per OP in a patient with IM myoma(ta) who underwent myomectomy prior to ART was calculated as the cost of one ART cycle plus median perioperative costs of surgery ($25,439) divided by the median likelihood of OP per ART cycle in a patient status post IM myomectomy (38.5%), yielding costs per OP of $66,075 via IM myomectomy followed by one ART cycle. Therefore, we found that at the median, ART success rates reported that post myomectomy surgery to remove IM fibroid(s) was a cost-effective intervention with savings of $6,280 per OP.
However, since the reported ranges of OPRs for ART with vs. without myomectomy were overlapping and wide (online suppl. table 2), we conducted a sensitivity analysis to determine the cost per OP across the range of OPRs reported in the literature for conservative vs. surgical management strategies. We again calculated cost per OP as the cost of treatment(s) for each strategy divided by the reported likelihood of OP with that strategy. The sensitivity analysis was performed using all of the possible OPRs over the range reported for each given treatment. The cost per OP was then plotted against the range of reported OPRs (online suppl. fig. 3 ). At a given cost per OP, the improvement in OPR that was required via pre-ART surgery in order to justify its use from a cost per OP perspective was represented by the difference between in situ and myomectomy OPRs. For example, if the OPR with IM myoma(ta) in situ was 27.5%, to justify surgery from a cost perspective, pre-ART myomectomy would need to improve the OPR by 17.1% or more. Sensitivity analysis data are further described in online supplemental table 4.
Our sensitivity analysis yielded several findings. Pre-ART IM myomectomy was always cost effective when the OPR among women with in situ myomas was <15.4% (corresponding to $101,756 cost per OP). Reported OPRs following IM myomectomy (25-52.0%) all yielded a cost per OP <$101,756 (online suppl. fig. 3, table 3 ). ART in the setting of IM myomas may have very poor outcomes, with OPRs as low as 12%, resulting in costs per OP upwards of $130,000; therefore, from a cost perspective, patients with IM fibroids that significantly worsened ART prognosis to <15.4% always benefited from pre-ART myomectomy.
If OPR with in situ myomas was 15.4-31.4%, cost effectiveness depended on the amount of improvement in OPR obtained from surgery: IM myomectomy needed to produce an improvement of at least 9.6% in OPR to be cost effective (online suppl. fig. 3, table 4 ). The range of improvement in OPR needed to be derived from surgery was 9.6-19.5%, depending on the OPR for ART with in situ myomas. As expected, the greater the OPR from ART with in situ myoma(ta), the greater the improvement in OPR needed to justify surgery from a cost per OP perspective. The reported range of OPRs for ART post IM myomectomy indicated that for all patients with IM fibroids, surgery was potentially cost effective, since the high end of the reported range of OPR post myomectomy slightly exceeded 50.9%.
Overall, our results indicated that myomectomy prior to ART was cost effective when fibroid(s) severely impaired chances of ART success (OPR <15.4%). Myomectomy reduced cost per OP for fibroids, causing a lesser impact on outcomes only when it resulted in a large improvement in OPR. The smaller the detriment in OPR associated with the fibroids, the greater the benefit needed from surgery in order to financially justify its use.
Discussion
Implantation rate per cycle is decreased in the presence of IM fibroids [20] . This analysis determined several guidelines to aid patients and clinicians in determining whether surgery for IM fibroids, prior to ART, is cost effective. Importantly, myomectomy was always cost effective if OPR with in situ myoma(s) was severely impaired (<15.4%). We interpret these results to indicate that for patients with IM fibroid(s) that significantly reduce implantation rates and/or increase spontaneous abortion rates, myomectomy is indicated. This finding was perhaps expected and certainly reassuring, as removal of such fibroids prior to ART is common clinical practice. Furthermore, it is of practical significance; IM myomectomy for the sole indication of infertility is often not covered by medical insurance in the United States [21] .
Our model also yielded useful information for patients whose fibroids have lesser impact. Here, cost effectiveness is dependent on the degree of improvement in OPR derived from surgery. In these cases, a significant improvement (>9.6%) must be obtained. For these patients, the cost effectiveness of surgery is not as clear as for patients at the extremes. Knowing the degree of improvement in ART success needed from surgery to be cost effective holds clinical value. Radiographic studies, the surgeon's ability, and resources of the surgical setting can be assessed. The surgeon can then estimate whether a given surgery might provide appropriate cost benefit to a given patient, warranting its use pre-ART.
Our analysis is novel and provides practical information regarding a commonly encountered clinical situation. To our knowledge, no previous studies have addressed the question of whether IM myomectomy is cost effective in terms of lowering the cost of live birth from ART. Myomectomy performed solely for the indication of infertility is generally not covered by medical insurance to the same extent as that performed for 'gynecologic' indications. Infertile patients with fibroids are often faced with the difficult decision of whether to undergo surgery prior to ART [21, 22] . The expense of the additional procedure may be a significant consideration, in addition to its risks, delays, and other inconveniences. The information obtained from our model may prove useful in counseling patients with IM fibroids who are deciding whether to proceed directly with ART vs. those undergoing surgery. The information may also be useful to insurers providing fertility benefits in determining whether, and to what extent, myomectomy for IM fibroids should be included.
Our study has several limitations. Decision tree models are inherently limited by the accuracy and precision of their data inputs. Inputs for our model were derived from an extensive search of the published literature on ART outcomes in patients with IM fibroids with/without myomectomy [6, [11] [12] [13] [14] [15] [16] [17] . However, current data provide wide ranges of outcomes for ART post myomectomy. Therefore, one could conclude that there is insufficient literature to determine the cost effectiveness of pre-ART myomectomy. Sensitivity analyses compare values within a range of reasonable uncertainty. They represent an accepted method to account for inputs with uncertain or wide ranges and here provide useful insights into the question of whether pre-ART myomectomy is cost effective [23] . Importantly, however, sensitivity analyses produce conditional outputs (i.e. if x, then y). In order to utilize our model to its maximum potential, the clinician needs to assign the likelihood of ART success given the patient's fibroid(s). Fortunately, characteristics that can be derived from imaging, such as size, number, and location, can guide such estimations [24] . In order to provide more precise estimates of the clinical and financial implications, further studies concerning the impact of IM fibroids on both natural fecundity and ART outcomes are warranted.
It is also important to recognize the simplicity of mathematical models relative to actual clinical decision making. For example, in this study, costs of canceled cycles and of those without transfer were not incorporated, as these were not expected to be impacted by myomectomy. Importantly, loss of individual productivity/absence from work was not included in our analysis, which focused on clinical rather than societal costs. From a societal perspective, considering the interval of lost work would likely further diminish cost effectiveness. Finally, our model could not explicitly take into account individual patient characteristics (such as age and parity) that have a bearing on ART success rates. However, because our sensitivity analysis uses the published range of preand post-myomectomy success rates, the clinician counseling patients may take these factors into account in determining where a given patient might be placed along the curves at his/her fertility center.
For all patients undergoing myomectomy, the chosen surgical approach may impact cost effectiveness. Depending on the region, a hospital's productivity, and other factors, the cost of myomectomy via laparotomy vs. laparoscopy with or without robotic-assistance may vary. According to Behera et al. [18] , robotic myomectomy is associated with significantly higher costs than abdominal and laparoscopic myomectomy. Perioperative costs of abdominal and laparoscopic myomectomy are more similar. Furthermore, perinatal outcomes following abdominal and laparoscopic myomectomy are similar [25] . While abdominal myomectomy is associated with lower procedural costs, postoperative costs are greater due to the longer hospital stay. For these reasons, we based the range of cost inputs for IM myomectomy in our model on the available literature of perioperative costs of abdominal and laparoscopic myomectomy only. Including the costs associated with robotic myomectomy, one would expect pre-ART IM myomectomy to be less cost effective on a cost-per-live-birth basis.
Conclusion
We conclude that cost effectiveness of myomectomy for IM fibroids prior to undergoing ART is dependent upon the degree to which the fibroid(s) worsen the likelihood of OP. Due to the heterogeneity of available studies providing model inputs, our model is unable to give precise guidance with regard to thresholds for these factors, and clinical judgment must be used. It is always cost effective to remove fibroids that cause an extremely severe detriment in OPR. When determining necessary pre-ART procedures, practitioners must incorporate a cost/ benefit ratio into their recommendations for patients. From a cost perspective, in cases where the goal of surgery is improvement in ART outcome, myomectomy for IM fibroids should be utilized sparingly.
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